Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
Molecular Profiling in mHSPC: Informing Treatment Selection
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Targeting PTEN: Why It Matters
IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
Florence Odufalu, MD
Ugo Iroku, MD, MHS
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
David T. Rubin, MD
Michael Dolinger, MD, MBA
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
Case: Implementing ADT Intensification in mHSPC
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
Robert D. Suh, MD
Ashwin Basavaraj, MD
Mary Salvatore, MD, MBA
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD
Kristi Orbaugh, MSN, RNP, AOCN
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.